標普：中東戰爭正通過能源價格上漲影響波蘭，但迄今爲止該國經濟仍保持韌性。

Moderna raised its full-year revenue guidance to growth of 15–25% (up from prior 10%) and reported its first quarterly profit since 2024, driven by a sharp year‑on‑year rebound in COVID‑19 vaccine sales; third‑quarter results beat a Street consensus that had forecast a loss. The company is shifting toward oncology; its Merck‑partnered mRNA skin‑cancer vaccine intismeran posted positive late‑stage trial results, and Moderna said the drug could win US approval next year — an outcome it called an important breakthrough for its mRNA platform. Moderna shares have rallied more than 700% YTD through Thursday.

The EU Council agreed a position to delay implementation of the EU methane regulation by one year.